An interventional study of UroAmp Test (Convergent Genomics, Inc.) in Non-muscle Invasive Bladder Cancer (NMIBC), sponsored by Lahey Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Lahey Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.
Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 46th largest by planned enrollment of the 93 interventional ones that give a count, is one of 11 that started in 2025, is one of 4 with no phase, reaches primary completion later than 46 of the 59 other live ones, and was the 101st registered.
295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Sites in United States
Ages 18+
Natera, Inc. · Sites in United States
Ages 18+
Janssen Research & Development, LLC · Sites in United States
Ages 18+
Protara Therapeutics · Sites in United States, Ukraine
Ages 18+
Michael A. O'Donnell · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 42 · Phase 3 27 · Phase 4 1
First in 2005; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is close to the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Median enrollment 55 across the 93 interventional studies, 408 across the 19 observational. Of the 46 that completed or were terminated, 25 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 114 have an industry lead sponsor. The 10 most frequent:
Lahey Clinic is the lead sponsor of 61 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Lahey Clinic has 1 study filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111235Phase 3CG Oncology, Inc.A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | 2026-11 |
| NCT05544552Tyra Biosciences, IncSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | 2026-11 |
| NCT06173349University of California, DavisPLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer | 2026-12 |
| NCT03945162Theralase® Technologies Inc.Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients | 2026-12 |
| NCT04375813Robert SvatekTrial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Less-frequent cystoscopy surveillance
Diagnostic Test: UroAmp Test (Convergent Genomics, Inc.)
Regular follow-ups and standard care
Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.
Number of cystoscopies
The rate of cystoscopies (cystoscopies per month), compared between the De-intensified and the standard surveillance arms, is the primary outcome measure.
Time frame: From enrollment to 24 months
Event-free survival
An event is defined as: high-grade recurrence, progression to muscle invasive disease, or metastatic disease
Time frame: From enrollment to 24 months
Recurrence-free survival
We will compare the rate of any recurrences (including low-grade) between the De-intensified and the standard surveillance groups
Time frame: From enrollment to 24 months
Patient-reported outcomes
The National Comprehensive Cancer Network Distress thermometer and the European Organisation For Research And Treatment Of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Non-Muscle Invasive Bladder Cancer (NMIBC-24) Module will be collected and compared between study arms
Time frame: From enrollment to 24 months
Interim Analysis
After 50% enrollment, the rate of conversion from low-risk on the utDNA test to high risk will be evaluated at 3 months. If this rate exceeds 50%, the study will be terminated for futility.
Time frame: 3 months
Plan to share: Undecided — Considering whether to involve other sites in the trial
Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-Muscle Invasive Bladder Neoplasms →
Lahey Clinic